Coverage
-
January 08, 2018
Cancer-drug maker Seattle Genetics Inc. on Friday asked a Washington federal court for a third time to dismiss a proposed securities fraud class action against it, saying the latest complaint still doesn't spell out how it supposedly knew it was engaged in wrongdoing.
2 other articles on this case.
View all »